Market Overview

Goldman Sachs Downgrades Aetna To Neutral

Share:
Related AET
David Einhorn Still Focused On Tech While Escaping Health Care In Q1
Sterne Agee CRT Downgrades Humana On 'Guidance Risk'
Select Medical Hits 52-Week High on Strong Q1 Performance - Analyst Blog (Zacks)

Analysts at Goldman Sachs downgraded Aetna (NYSE: AET) from Buy to Neutral.

The target price for Aetna has been lowered from $94.00 to $88.00.

Aetna shares have surged 24.00% over the past 52 weeks, while the S&P 500 index has gained 13.56% in the same period.

Aetna's shares dropped 0.61% to $77.84 in pre-market trading.

Latest Ratings for AET

DateFirmActionFromTo
May 2015Leerink SwannMaintainsOutperform
Apr 2015BarclaysMaintainsOverweight
Apr 2015Leerink SwannMaintainsOutperform

View More Analyst Ratings for AET
View the Latest Analyst Ratings

Posted-In: Goldman SachsDowngrades Analyst Ratings

 

Related Articles (AET)

Around the Web, We're Loving...

Get Benzinga's Newsletters